По вашему запросу найдено документов: 121

Страница 1 из 13

A RANDOMIZED PHASE 2 STUDY OF LONG-ACTING TRANSCON GH VS DAILY GH IN CHILDHOOD GH DEFICIENCY
Chatelain, Pierre, Malievskiy, Oleg, Radziuk, Klaudziya, Senatorova, Ganna, Abdou, Magdy O., Vlachopapadopoulou, Elpis, Skorodok, Yulia, Peterkova, Valentina, Leff, Jonathan A., Beckert, Michael (2017)
Context: TransCon Growth Hormone (GH) (Ascendis Pharma) is a long-acting recombinant sustained
Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
Maniatis, AK;, Casella, SJ;, Nadgir, UM;, Hofman, PL;, Saenger, P;, Chertock, ED;, Aghajanova, EM;, Korpal-Szczyrska, M;, Vlachopapadopoulou, E;, Malievskiy, O;, Chaychenko, T;, Cappa, M;, Song, WJ;, Mao, M;, Mygind, PH;, Smith, AR;, Chessler, S;, Komirenko, AS;, Beckert, M;, Aimee, D Shu, Paul, S Thornton (2022)
with lonapegsomatropin. Subjects in the United States switched to the TransCon hGH Auto-Injector when available
LONG-ACTING C-TERMINAL PEPTIDE-MODIFIED HGH (MOD-4023): RESULTS OF A SAFETY AND DOSE-FINDING STUDY IN GHD CHILDREN
Zelinska, N., Iotova, V., Skorodok, J., Malievsky, O., Peterkova, V., Samsonova, L., Rosenfeld, Ron G., Zadik, Zvi, Jaron-Mendelson, Michal, Koren, Ronit, Amitzi, Leanne, Raduk, Dmitri, Hershkovitz, Oren, Hart, Gili (2017)
doses, compared with daily recombinant human GH (r-hGH). Setting: The trial was conducted in 14
12-Month Effects of Once-Weekly and Twice-Monthly Administration of Hybrid Fc-Fused Human Growth Hormone, GX-H9, Treatment in Pediatric with GHD Deficiency
Malieyskiy, O., Mykola, A., Nataliya, Z., Bolshova, E.V., Senatorova, G., Oroszlan, G., Skorodok, J., Peterkova, V., Nataliya, C., Sorokman, T., Yang, S., Lee, J.E., Muzsnai, A., Hwang, J.S., Lee, S.Y., Choi, Y.J., Ji, H.J., Woo, J., Sung, Y.C. (2018)
GX-H9 is a long-acting form of recombinant human GH under clinical development for both adults
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium
Beyer, J., Collette, L., Sauve, N., Daugaard, G., Feldman, D.R., Tandstad, T., Tryakin, A., Stahl, O., Gonzalez-Billalabeitia, E., De Giorgi, U., Culine, S., de Wit, R., Hansen, A.R., Bebek, M., Terbuch, A., Albany, C., Hentrich, M., Gietema, J.A., Negaard, H., Huddart, R.A., Lorch, A., Cafferty, F.H., Heng, D.Y.C., Sweeney, C.J., Winquist, E., Chovanec, M., Fankhauser, C., Stark, D., Grimison, P., Necchi, A., Tran, B., Heidenreich, A., Shamash, J., Sternberg, C.N., Vaughn, D.J., Duran, I., Bokemeyer, C., Patrikidou, A., Cathomas, R., Assele, S., Gillessen, S. (2021)
Role of Optical Coherence Tomography in Diagnosis and Treatment of Patients with Acute Coronary Syndrome
Afolabi, A., Hu, SN., Wang, C., Zhu, YC., Mustafina, I., Lin, L., Zheng, GH., Zhe, CY., Jia, HB., Hou, JB., Yu, B. (2017)
Isatin-3-acylhydrazones with Enhanced Lipophilicity: Synthesis, Antimicrobial Activity Evaluation and the Influence on Hemostasis System
Bogdanov, AV, Voloshina, AD, Sapunova, AS, Kulik, NV, Bukharov, SV, Dobrynin, AB, Voronina, JK, Terekhova, NV, Samorodov, AV, Pavlov, VN, Mironov, VF (2022)
easily synthesized with high yields. XRD studies confirmed the presence of these compounds as trans
The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study
Lomakin, NV, Bakirov, BA, Protsenko, DN, Mazurov, VI, Musaev, GH, Moiseeva, OM, Pasechnik, ES, Popov, VV, Smolyarchuk, EA, Gordeev, IG, Gilyarov, MY, Fomina, DS, Seleznev, AI, Linkova, YN, Dokukina, EA, Eremeeva, AV, Pukhtinskaia, PS, Morozova, MA, Zinkina-Orikhan, AV, Lutckii, AA (2021)
The impact of cortisol treatment on free radical oxidation in traumatized clean-up workers 30 years after chernobyl nuclear disaster
Tseylikman, V., Davydovich, M., Tseylikman, O., Ullmann, E. (2019)
final con-centration of 10−5,10−6,10−7M. Red Blood Cells (RBCs) contentof lipid peroxidation (UE
Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
Deal, C, Steelman, J, Vlachopapadopoulou, E, Stawerska, R, Silverman, LA;, Phillip, M, Kim, HS, Ko, CW, Malievskiy, O, Cara, JF, Roland, CL, Taylor, CT, Valluri, SR, Wajnrajch, MP, Pastrak, A, Miller, BS (2022)
Context: Somatrogon is a long-acting recombinant human growth hormone (rhGH) in development

Страница 1 из 13

Google Scholar
OpenDoar

Фасеты

Авторы
Ключевые слова
Год